News | May 06, 2026
Pfizer powers ahead in 2026 with strong Q1 results as pipeline momentum builds
The pharmaceutical giant reported $14.5 billion in revenue, up 5% year-over-year, and reaffirmed its full-year outlook
The pharmaceutical giant reported $14.5 billion in revenue, up 5% year-over-year, and reaffirmed its full-year outlook
Approval marks the second generic semaglutide clearance in Canada and strengthens OneSource’s position in complex injectable CDMO programs
Lifts full-year outlook as obesity drug boom accelerates
Advisory from Apollo Spectra Hospitals highlights hydration, nutrition, and screening as key preventive measures
The collaboration will embed OpenAI’s advanced AI systems across Novo Nordisk’s global operations
CDSCO-approved therapy enters India’s fast-growing post-patent GLP-1 market with fully integrated API, formulation and pen manufacturing
GoodRx at a starting price of $149 per month—aligned with the lowest available discounted cash price at launch. The rollout includes nationwide pharmacy access
Novo Nordisk continues to position Wegovy as a cornerstone of its obesity treatment portfolio
The once-daily oral medication is approved for adults with obesity or overweight who have weight-related medical conditions
Hyderabad-based peptide specialist strengthens complex generics credentials as Apotex prepares for U.S. commercialization of semaglutide injection
Subscribe To Our Newsletter & Stay Updated
